20 assets in Hemophagocytic Syndrome

Therapeutic assets addressing Hemophagocytic Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Etoposide Hemophagocytic Syndrome	Beijing Tongren Hospital	P4	BBB (73)
Pegaspargase Hemophagocytic Syndrome	Beijing Tongren Hospital	P4	BB (69)
Adriamycin Hemophagocytic Syndrome	The First Affiliated Hospital of Soochow University	P4	BB (68)
Zanubrutinib Hemophagocytic Syndrome	The First Affiliated Hospital of Soochow University	P4	BB (65)
Rituximab Hemophagocytic Syndrome	The First Affiliated Hospital of Soochow University	P4	BB (64)
Thiotepa Hemophagocytic Syndrome	University of Florida	P2	BB (64)
L-Dep Hemophagocytic Syndrome	Beijing Friendship Hospital	P3	B (60)
Cyclophosphamide Hemophagocytic Syndrome	Masonic Cancer Center, University of Minnesota	P2	B (57)
Alemtuzumab Hemophagocytic Syndrome	Washington University School of Medicine	P2	CCC (53)
Busulfanum Hemophagocytic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Clofarabine Hemophagocytic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Cyclosporin A Hemophagocytic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Fludarabine Hemophagocytic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Hpc, Cord Blood Hemophagocytic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Melphalan Hemophagocytic Syndrome	Washington University School of Medicine	P2	CCC (53)
Golidocitinib Hemophagocytic Syndrome	Beijing Tongren Hospital	P1/2	CC (47)
Mitoxantrone Hemophagocytic Syndrome	Beijing Tongren Hospital	P1/2	CC (47)
Icaspase9-Transduced T Cells Hemophagocytic Syndrome	Baylor College of Medicine	P1	CC (41)
Rimiducid Hemophagocytic Syndrome	Bellicum Pharmaceuticals	P1	CC (41)
Mesna Hemophagocytic Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)